Boston Trust Walden Corp Grows Stake in Zoetis Inc. $ZTS

Key Points

• Boston Trust Walden Corp increased its stake in Zoetis Inc. (NYSE:ZTS) by 94.8%, acquiring an additional 46,450 shares, bringing its total to 95,468 shares valued at approximately $14.9 million.
• Zoetis recently reported earnings of $1.76 per share for the quarter, exceeding analysts' expectations, and raised its full-year EPS guidance to a range of $6.30-$6.40.
• The company declared a quarterly dividend of $0.50 per share, which will be paid on December 2nd, representing an annualized yield of 1.4%.

Boston Trust Walden Corp boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 94.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,468 shares of the company's stock after purchasing an additional 46,450 shares during the quarter. Boston Trust Walden Corp's holdings in Zoetis were worth $14,888,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock valued at $6,842,222,000 after acquiring an additional 189,287 shares during the period. Polen Capital Management LLC increased its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Northern Trust Corp increased its holdings in shares of Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock valued at $1,071,032,000 after acquiring an additional 78,508 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock valued at $847,293,000 after acquiring an additional 109,791 shares during the period. Finally, Brown Advisory Inc. increased its holdings in shares of Zoetis by 7.6% in the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock valued at $725,866,000 after acquiring an additional 312,746 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $143.45 on Wednesday. The stock has a 50-day moving average of $148.98 and a two-hundred day moving average of $154.11. Zoetis Inc. has a one year low of $139.34 and a one year high of $196.55. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market cap of $63.58 billion, a P/E ratio of 24.69, a P/E/G ratio of 2.28 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter in the previous year, the firm posted $1.56 EPS. The firm's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis's payout ratio is currently 34.42%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Weiss Ratings reissued a "hold (c-)" rating on shares of Zoetis in a research report on Wednesday, October 8th. Finally, Argus reissued a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $196.71.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.